Non-Alcoholic Steatohepatitis (NASH)
Non-Alcoholic Steatohepatitis (NASH) is a liver condition characterized by fat accumulation in the liver, leading to inflammation and damage, often without any history of alcohol use.
Cirrhosis Due to NASH/MASH: Efruxifermin Study
We are testing a new medication, Efruxifermin, for people with compensated cirrhosis from NASH/MASH. The study aims to see if it improves liver health and reduces related health risks compared to a placebo.
>2 yearsConfirmation phase (III)Cost ReimbursementInvestigational MedicinesInjectionEndocrinologyHepatology
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a condition where fat builds up in the liver due to metabolic dysfunction, leading to inflammation and potential liver damage.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 80 years old?
- Do you have type 2 diabetes?
- Are you pregnant or breastfeeding?
- Have you lost more than 10% of your weight in the last 3 months?
- Is your body mass index (BMI) 25 or higher?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Efruxifermin
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Universitaire D'Angers
Hépato-Gastroentérologie
Angers, France
Hopital De La Croix-Rousse
Hépato-gastroentérologie
Caluire-et-Cuire, France
Hopital Beaujon
Hépatologie
Clichy, France
Sponsor: Akero Therapeutics Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.